FAQ: QUASAR Long Term Extension Interim Analysis

FAQ: QUASAR Long Term Extension Interim Analysis

Thank you to Johnson & Johnson for their support on this FAQ Video Module. In this educational video, Jamie Brogan, APRN, from Northwestern Medicine, reviews the latest QUASAR long-term extension data evaluating the efficacy and safety of guselkumab in adults with moderate to severe ulcerative colitis. This discussion highlights approximately two years of follow-up data, offering healthcare providers valuable insight into the long-term durability of treatment response, clinical remission, endoscopic improvement, and overall safety outcomes associated with guselkumab maintenance therapy. Jamie walks through the key findings from the ongoing multicenter extension study, including sustained clinical remission rates, corticosteroid-free remission, endoscopic healing, and histologic-endoscopic mucosal improvement through week 92. The video also reviews the maintenance dosing strategies of guselkumab, including 100 mg every 8 weeks and 200 mg every 4 weeks, and discusses how patients who responded during earlier phases of treatment maintained those responses over time. In addition, the presentation covers important long-term safety findings, including rates of serious infections and adverse events observed throughout the study. This video is designed for gastroenterology APPs, nurse practitioners, physician assistants, gastroenterologists, and healthcare professionals looking to stay current on emerging ulcerative colitis therapies, long-term biologic data, and evolving treatment goals in inflammatory bowel disease (IBD). For more educational content on ulcerative colitis, Crohn’s disease, gastroenterology, and hepatology, visit the GHAPP Digital Hub and the GHAPP ACE app.

Medication Review: Guselkumab IV vs SC Formulation

Thank you to Johnson & Johnson for their support on this Medication Review Video Module. In this quick educational video, Angelina Collins, NP, from the University of California San Diego Inflammatory Bowel Disease Center, discusses an important question in Crohn’s disease treatment. This overview breaks down the key findings from the GALAXI and GRAVITI clinical trials in a clear, practical way, helping healthcare providers better understand the effectiveness and safety of both treatment approaches for patients with moderate to severe Crohn’s disease. Angelina explains the differences between IV and subcutaneous induction dosing, maintenance treatment options, and how these choices can support shared decision-making between providers and patients. Whether patients are new to advanced therapies or have previous biologic experience, this discussion highlights how both induction options may provide strong results without compromising safety. This video is designed for gastroenterology APPs, nurse practitioners, physician assistants, gastroenterologists, and healthcare professionals looking for practical insights into Crohn’s disease management and evolving IBD treatment strategies. For more GI and hepatology education, visit the GHAPP Digital Hub and the GHAPP ACE app.

FAQ: Recognizing OHE Risk in Patients with Chronic Liver Disease

Thank you to Salix for the support on this FAQ Video Module. This educational FAQ module, featuring Mikhail Alper, PA-C focuses on recognizing risk factors and early clinical indicators of Overt Hepatic Encephalopathy (OHE) in patients with chronic liver disease and cirrhosis. A central focus is placed on subtle and often underrecognized manifestations of OHE risk, including disrupted sleep, wake cycles, daytime somnolence, intermittent confusion, and short-term memory lapses. These early signs may be easily missed without targeted questioning and careful clinical evaluation, particularly in younger or ambulatory patients with cirrhosis. Learn how proactive screening and early recognition of cognitive and behavioral changes can support timely identification of OHE risk in chronic liver disease. The review highlights the importance of clinician awareness in preventing progression to more severe neurocognitive impairment and supporting earlier intervention strategies in at risk patients. For more educational content visit the GHAPP Digital Hub or the GHAPP ACE app.

FAQ: Phase 3 GALAXI 2 & 3: Extraintestinal Manifestations In Moderate to Severe Crohn’s Disease

Thank you to Johnson & Johnson for the support on this FAQ Video Module. This FAQ video features Janette Villalon, PA, who reviews the role of guselkumab in treating extraintestinal manifestations in patients with moderately to severely active Crohn’s disease. In this expert-led discussion, she summarizes findings from the GALAXI 2 and GALAXI 3 clinical trials presented at a 2026 medical congress, which used a treat-through study design intended to reflect real-world clinical practice. The focus of the analysis is on how patients with Crohn’s disease respond over time when treated with guselkumab compared to placebo. The data presented focuses on key outcomes such as improvement and resolution of extraintestinal manifestations, including joint and skin symptoms, along with measures like steroid-free remission and the emergence of new symptoms over time. At baseline, a notable proportion of patients in both the guselkumab and placebo groups had extraintestinal involvement, most commonly arthralgia, with skin manifestations occurring less frequently. This educational FAQ highlights how clinicians are evaluating guselkumab as part of a broader strategy for managing Crohn’s disease, with attention to both symptom control and durability of response over time. It provides practical insights for gastroenterology advanced practice providers and healthcare professionals as they balance effectiveness, long-term disease control, and comprehensive care of patients with inflammatory bowel disease in clinical practice. Visit the GHAPP Website, GHAPP Digital Hub or GHAPP ACE app for additional educational content.

Medication Review: Monotherapy vs. Combination Therapy: Relevance in IBD Treatment Strategy

Thank you to Celltrion for the support on this Medication Review Video Module. This medication review explores the evolving role of monotherapy versus combination therapy in the treatment of inflammatory bowel disease (IBD), with a focus on biologic optimization and patient-centered treatment strategies. In this expert-led discussion, Brooke Hodnick, PA, from Texas Digestive Disease Consultants, reviews the clinical rationale behind combining biologic therapies such as infliximab with immunomodulators, including methotrexate and thiopurines, to reduce immunogenicity, improve biologic drug levels, and enhance long-term treatment outcomes in ulcerative colitis and Crohn’s disease. The presentation highlights pivotal clinical trials including SONIC and UC SUCCESS, which demonstrated improved remission rates and mucosal healing with combination therapy involving TNF inhibitors. Current recommendations from the American Gastroenterological Association (AGA) and American College of Gastroenterology (ACG) supporting infliximab combination therapy are also discussed. The review also examines the growing interest in biologic monotherapy approaches, particularly with subcutaneous infliximab formulations. Data from the LIBERTY Crohn’s and LIBERTY UC trials are explored, demonstrating stable and sustained pharmacokinetic drug concentrations through two years of treatment without the need for additional immunomodulators. This PK-driven monotherapy strategy may help reduce long-term immunosuppressive burden while maintaining efficacy in select patients with IBD. Important safety considerations are addressed, including infection risk, lymphoma risk, hepatosplenic T-cell lymphoma, and non-melanoma skin cancer associated with thiopurine use, especially in older adults and younger male patients receiving prolonged combination therapy. Learn how clinicians are balancing efficacy, safety, immunogenicity, and treatment simplification when selecting monotherapy versus combination therapy for ulcerative colitis and Crohn’s disease. This educational medication review provides practical insights for gastroenterology advanced practice providers and healthcare professionals managing complex IBD patients in clinical practice. Visit the GHAPP Website, GHAPP Digital Hub or GHAPP ACE app for additional educational content.